 |
|
|
| |
Achievement of Virologic Suppression in the PROMISE-US Study (Ibalizumab) in Subjects Viremic at Baseline
|
| |
| |
CROI 2025 SF March 9-12
Smitha Gudipati1, Princy N. Kumar2, Charlotte-Paige Rolle3, Christina Harbison4, Namrata Shah5, and Kaitlin R.A. Anstett6 on behalf of the PROMISE-US Investigators
1Henry Ford Hospital, Detroit, MI, USA, 2Georgetown University School of Medicine, Washington, DC, USA, 3Orlando Immunology Center, Orlando, FL, USA, 4Prism Health North Texas, Dallas, TX, USA,
5Whitman Walker Institute, Washington DC, USA, 6Theratechnologies, Inc., Montreal, QC, Canada
|
| |
|
|
|
|
|
